The purpose of this study is to assess the effect of food on the drug levels of Admilparant
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
56
Specified dose on specified days
Local Institution - 0002
Lenexa, Kansas, United States
Local Institution - 0001
Salt Lake City, Utah, United States
Maximum observed plasma concentration (Cmax)
Time frame: Up to 13 days
Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
Time frame: Up to 13 days
Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF))
Time frame: Up to 13 days
Time of maximum observed plasma concentration (Tmax)
Time frame: Up to 13 days
Terminal half-life (T-HALF)
Time frame: Up to 13 days
Apparent total body clearance (CLT/F)
Time frame: Up to 13 days
Apparent volume of distribution (Vz/F)
Time frame: Up to 13 days
Number of participants with adverse events (AEs)
Time frame: Up to 13 days
Number of participants with a change in clinical laboratory values
Time frame: Up to 13 days
Number of participants with a change in vital sign measurements
Time frame: Up to 13 days
Number of participants with a change in physical examination results
Time frame: Up to 13 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Number of participants with a change in 12-lead electrocardiogram (ECG) results
Time frame: Up to 13 days